

Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing. The investors included IMM Investment, KDB Investment and Atinum.
Source: Press Release
Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing.
Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing. The investors included IMM Investment, KDB Investment and Atinum.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination